Mohammad Jahanzeb

MedicineEconomics, Econometrics and FinanceBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)”.

A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07417-4

N/A

0.215DataRank · unranked

3 citations

Anne O’Neill, Ingrid A. Mayer, Carlos L. Arteaga, Ximing J. Yang, Lynne I. Wagner +17 more

A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)

Research Square(2024)10.21203/rs.3.rs-4295044/v1

N/A

0DataRank · unranked

0 citations

Anne O’Neill, Ingrid A. Mayer, Carlos L. Arteaga, Ximing J. Yang, Lynne I. Wagner +17 more